Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06497556 · ClinicalTrials.gov registry record · Phase 3
A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer
A Phase 3 study of Non-Small Cell Lung Cancer and KRAS G12C Lung Cancer, sponsored by Hoffmann-La Roche.
- Active
- Registry status
- Phase 3
- Development phase
- 338
- Enrollment target
- 20
- Study locations
NCT06497556 is a Phase 3 study of Non-Small Cell Lung Cancer and KRAS G12C Lung Cancer that is active but no longer recruiting, run by Hoffmann-La Roche. The registered enrollment target is 338 participants, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (49% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT06497556, a Phase 3 study of Non-Small Cell Lung Cancer and KRAS G12C Lung Cancer, is active but no longer recruiting, sponsored by Hoffmann-La Roche.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 338 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the safety and efficacy of divarasib compared to locally approved KRAS G12C inhibitors (sotorasib or adagrasib) in participants with KRAS G12C-positive (KRAS G12C +) advanced or metastatic non-small cell lung cancer (NSCLC).
Conditions Studied
Interventions
- DRUG Divarasib
- DRUG Adagrasib
- DRUG Sotorasib
Study Locations (20)
California
- Los Angeles Cancer Network - Los Angeles
- UCLA Hematology / Oncology Clinic - Los Angeles
- University of California, San Francisco - San Francisco
Florida
- University of Miami - Miami
- Florida Cancer Specialists - North;725 6th Ave South (St. Petersburg) - St. Petersburg
Michigan
- University of Michigan - Ann Arbor
- Cancer and Hematology Centers of Western Michigan - Grand Rapids
Oregon
- Oncology Associates of Oregon, P.C - Eugene
- Oregon Health & Science University - Portland
Pennsylvania
- Fox Chase Cancer Center - Philadelphia
- Allegheny Cancer Center - Pittsburgh
Arizona
- Banner Health MD Anderson AZ - Gilbert
Connecticut
- Yale Cancer Center - New Haven
Illinois
- University of Chicago Medical Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 338 participants |
| Start Date | 2024-09-23 |
| Est. Completion | 2029-11-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06497556
The ClinicalTrials.gov registry entry for NCT06497556 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 338 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (49% lower). The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 3 interventions - of which Divarasib is the first listed.
NCT06497556 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Florida, Michigan.
Frequently Asked Questions
What is clinical trial NCT06497556 about?
NCT06497556 is a clinical study titled "A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer". The purpose of this study is to assess the safety and efficacy of divarasib compared to locally approved KRAS G12C inhibitors (sotorasib or adagrasib) in participants with KRAS G12C-positive (KRAS G12C +) advanced or metastatic non-small cell lung cancer (NSCLC).
What is the current status of trial NCT06497556?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 338 participants. The study started on 2024-09-23. Estimated completion is 2029-11-30.
What conditions does trial NCT06497556 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer.
What interventions are being tested in trial NCT06497556?
The interventions under investigation include: Divarasib (DRUG), Adagrasib (DRUG), Sotorasib (DRUG).
Who is sponsoring clinical trial NCT06497556?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06497556 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
RECRUITING · Phase 3
-
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
RECRUITING · Phase 3
-
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
RECRUITING · Phase 3
-
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
RECRUITING · Phase 3
-
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.